Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders
Open Access
- 1 January 2008
- journal article
- review article
- Published by Hindawi Limited in PPAR Research
- Vol. 2008, 1-14
- https://doi.org/10.1155/2008/679137
Abstract
Overweight and obesity lead to an increased risk for metabolic disorders such as impaired glucose regulation/insulin resistance, dyslipidemia, and hypertension. Several molecular drug targets with potential to prevent or treat metabolic disorders have been revealed. Interestingly, the activation of peroxisome proliferator-activated receptor (PPAR), which belongs to the nuclear receptor superfamily, has many beneficial clinical effects. PPAR directly modulates gene expression by binding to a specific ligand. All PPAR subtypes (and) are involved in glucose metabolism, lipid metabolism, and energy balance. PPAR agonists play an important role in therapeutic aspects of metabolic disorders. However, undesired effects of the existing PPAR agonists have been reported. A great deal of recent research has focused on the discovery of new PPAR modulators with more beneficial effects and more safety without producing undesired side effects. Herein, we briefly review the roles of PPAR in metabolic disorders, the effects of PPAR modulators in metabolic disorders, and the technologies with which to discover new PPAR modulators.
Keywords
Funding Information
- Korea Science and Engineering Foundation (R01-2006-000-10145-0)
This publication has 123 references indexed in Scilit:
- MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacityProceedings of the National Academy of Sciences of the United States of America, 2007
- Selective Modulators of PPAR-Activity: Molecular Aspects Related to Obesity and Side-EffectsPPAR Research, 2007
- The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiationCellular Signalling, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Adiponectin, obesity, and cardiovascular diseaseBiochimie, 2004
- Different ways to regulate the PPARα stabilityBiochemical and Biophysical Research Communications, 2004
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994
- Studies on antidiabetic agents. I. Synthesis of 5-(4-(2-methyl-2-phenylpropoxy)-benzyl)thiazolidine-2,4-dione (AL-321) and related compounds.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982